[ad_1]
AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Globus Medical, Inc. plunged 5.6% on Friday, closing at $76.36, after a pair of Wall Street firms slashed their price targets on the medical device maker. The sell-off came as both Truist Securities and RBC Capital lowered their outlook on the stock, trimming targets by an average of 8.5% despite maintaining positive ratings.
The downgrades hit hard. Truist Securities kept its Buy rating but cut its price target to $100 from $115, while RBC Capital maintained an Outperform rating while reducing its target to $115 from $120. The average new price target of $108 still implies upside from current levels, but the coordinated reduction from two major firms sent a cautionary signal to investors who pushed shares lower in Friday’s session.
Volume spiked as investors reacted. The stock traded 1.1M shares as the market absorbed the analyst actions. At a market capitalization of $10.4B, Globus Medical remains a significant player in the medical devices space, but the dual downgrades raise questions about near-term momentum even as both firms retained constructive views on the stock.
The timing matters. When multiple analysts move in the same direction on the same day, it often reflects shared concerns about fundamentals, valuation, or sector dynamics. Both Truist and RBC opted to preserve their positive ratings while recalibrating expectations, suggesting the firms see continued long-term value but are tempering their near-term outlook. The fact that both maintained Buy-equivalent ratings indicates they’re not abandoning the story, but the 8.5% average target reduction is substantial enough to trigger profit-taking.
Investors now face a recalibration. The question is whether today’s drop represents an overreaction to target cuts from firms that still rate the stock positively, or whether the analysts are signaling softer trends ahead. With the stock down sharply but still backed by Outperform and Buy ratings, the disconnect between sentiment and price action will likely dominate trading in coming sessions.
What to Watch: Investors should monitor whether additional analysts follow with target adjustments, and watch for any company commentary that might address the concerns driving Wall Street’s recalibration. The next earnings report will be critical in determining whether the target cuts prove prescient or premature.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.
[ad_2]
Source link